CK-2017357 is being tested in combination with riluzole, and Neuralstem will test delivery of its stem cells into the cervical region of the spinal cord
Article Highlights:
- Two human clinical trials to test experimental therapies in ALS are moving forward.
- After having tested its experimental therapy CK-2017357 in people with ALS who weren't taking riluzole, biotechnology company Cytokinetics has now begun the second part of its phase 2 trial, in which the two drugs will be tested in combination.
- Biotherapeutics company Neuralstem will begin testing the safety of transplanting its neural stem cells into the cervical (neck) region of people with ALS.
